Screening for Chronic Obstructive Pulmonary Disease (COPD) in an Urban HIV Clinic: A Pilot Study

AIDS Patient Care and STDs

Volumn 29, Issue 5, 2015, Pages 232-239

  Shirley, Daniel K ^a   Kaner, Robert J ^b   Glesby, Marshall J ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PILOT STUDY; SENSITIVITY AND SPECIFICITY; SPIROMETRY; ADVERSE EFFECTS; AGED; HIV INFECTIONS; LUNG; MASS SCREENING; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RISK FACTOR; SMOKING; UNITED STATES;

ADULT; AGED; AMBULATORY CARE FACILITIES; FEMALE; FORCED EXPIRATORY VOLUME; HIV INFECTIONS; HUMANS; LUNG; MALE; MASS SCREENING; MIDDLE AGED; NEW YORK CITY; PEAK EXPIRATORY FLOW RATE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SMOKING; SPIROMETRY; SURVEYS AND QUESTIONNAIRES;

EID: 84930008818     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0265     Document Type: Article

References (58)

1. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance-United States, 1999-2011. Chest 2013;144:284-305.
2. Gingo MR, Morris A, Crothers K. Human immunodeficiency virus-associated obstructive lung diseases. Clin Chest Med 2013;34:273-282.
3. Schwarcz SK, Vu A, Hsu LC, Hessol NA. Changes in causes of death among persons with AIDS: San Francisco, California, 1996-2011. AIDS Patient Care STDS 2014;28:517-523.
4. Leung JM, Liu JC, Mtambo A, et al. The determinants of poor respiratory health status in adults living with human immunodeficiency virus infection. AIDS Patient Care STDS 2014;28:240-247.
5. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 2007;28:575-587, vi.
6. Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: A sample of smokers facing multiple challenges. AIDS Educ Prev 2009;21:54-64.
7. Lifson AR, Lando HA. Smoking and HIV: Prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012;9:223-230.
8. Mamary EM, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS 2002;16:39-42.
9. Reynolds NR. Cigarette smoking and HIV: More evidence for action. AIDS Educ Prev 2009;21:106-121.
10. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: Prevalence, frequency, and opportunities for cessation. AIDS Behav 2010;14:824-835.
11. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000;132:369-372.
12. Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 2011;8:313-319.
13. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-1026.
14. Cota-Gomez A, Flores AC, Ling X-F, Varella-Garcia M, Flores SC. HIV-1 Tat increases oxidant burden in the lungs of transgenic mice. Free Radic Biol Med 2011;51:1697-1707.
15. Gil L, Martínez G, González I, et al. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res 2003;47:217-224.
16. Kaner RJ, Santiago F, Crystal RG. Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1(+) smokers with early emphysema. J Leukoc Biol 2009;86:913-922.
17. Lassiter C, Fan X, Joshi PC, et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther 2009;6:1.
18. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-2365.
19. Shipley TW, Kling HM, Morris A, et al. Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS. J Infect Dis 2010;202:302-312.
20. Petrache I, Diab K, Knox KS, et al. HIV associated pulmonary emphysema: A review of the literature and inquiry into its mechanism. Thorax 2008;63:463-469.
21. Buhl R, Meyer A, Vogelmeier C. Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. Chest 1996;110:267S-272S.
22. Micoli KJ, Mamaeva O, Piller SC, et al. Point mutations in the C-terminus of HIV-1 gp160 reduce apoptosis and calmodulin binding without affecting viral replication. Virology 2006;344:468-479.
23. Mocchegiani E, Giacconi R, Costarelli L. Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: Genetic factors and treatment implications. Curr Opin Pulm Med 2011;17:S11-S19.
24. Morris A, Alexander T, Radhi S, et al. Airway obstruction is increased in pneumocystis-colonized human immunodeficiency virus-infected outpatients. J Clin Microbiol 2009;47:3773-3776.
25. Sundaram M, Saghayam S, Priya B, et al. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis 2008;12:e61-e66.
26. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest 1997;112:785-788.
27. Treitinger A, Spada C, Verdi JC, et al. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. Eur J Clin Invest 2000;30:454-459.
28. Wood KL, Knox KS, Wang Y, Day RB, Schnizlein-Bick C, Twigg HL. Apoptosis of CD57+ and CD57- lymphocytes in the lung and blood of HIV-infected subjects. Clin Immunol 2005;117:294-301.
29. Yearsley MM, Diaz PT, Knoell D, Nuovo GJ. Correlation of HIV-1 detection and histology in AIDS-associated emphysema. Diagn Mol Pathol 2005;14:48-52.
30. Shirley DK, Kesari RK, Glesby MJ. Factors associated with smoking in HIV-infected patients and potential barriers to cessation. AIDS Patient Care STDS 2013;27:604-612.
31. Drummond MB, Merlo CA, Astemborski J, et al. The effect of HIV infection on longitudinal lung function decline among IDUs: A prospective cohort. AIDS 2013;27:1303-1311.
32. Kristoffersen US, Lebech A-M, Mortensen J, Gerstoft J, Gutte H, Kjaer A. Changes in lung function of HIV-infected patients: A 4.5-year follow-up study. Clin Physiol Funct Imaging 2012;32:288-295.
33. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-1178.
34. Jenkins CR, Jones PW, Calverley PMA, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59.
35. Spencer S, Calverley PM, Sherwood Burge P, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128.
36. Bridevaux P-O, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz J-M, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008;63:768-774.
37. Kelly CA, Gibson GJ. Relation between FEV1 and peak expiratory flow in patients with chronic airflow obstruction. Thorax 1988;43:335-336.
38. Llewellin P, Sawyer G, Lewis S, et al. The relationship between FEV1 and PEF in the assessment of the severity of airways obstruction. Respirology 2002;7:333-337.
39. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: Cross sectional survey. BMJ 2003;327:653-654.
40. Perez-Padilla R, Vollmer WM, Vázquez-García JC, Enright PL, Menezes AMB, Buist AS. Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? Int J Tuberc Lung Dis 2009;13:387-393.
41. Hansen EF, Vestbo J, Phanareth K, Kok-Jensen A, Dirksen A. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:690-693.
42. Badgett RG, Tanaka DJ, Hunt DK, et al. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? Am J Med 1993;94:188-196.
43. Badgett RG, Tanaka DJ, Hunt DK, et al. The clinical evaluation for diagnosing obstructive airways disease in high-risk patients. Chest 1994;106:1427-1431.
44. Nelson SB, LaVange LM, Nie Y, et al. Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general population. Chest 2012;142:358-366.
45. Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD 2008;5:85-95.
46. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
47. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
48. Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc 2011;8:313-319.
49. Shirley DK, Kaner RJ, Glesby MJ. Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Clin Infect Dis 2013;57:275-282.
50. Morris A, George MP, Crothers K, et al. HIV and chronic obstructive pulmonary disease: Is it worse and why? Proc Am Thorac Soc 2011;8:320-325.
51. Drummond MB, Kirk GD, Astemborski J, et al. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax 2012;67:309-314.
52. Crothers K, McGinnis K, Kleerup E, et al. HIV infection is associated with reduced pulmonary diffusing capacity. J Acquir Immune Defic Syndr 2013;64:271-278.
53. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011;183:388-395.
54. Matthews AK, Conrad M, Kuhns L, Vargas M, King AC. Project Exhale: Preliminary evaluation of a tailored smoking cessation treatment for HIV-positive African American smokers. AIDS Patient Care STDS 2013;27:22-32.
55. Moadel AB, Bernstein SL, Mermelstein RJ, Arnsten JH, Dolce EH, Shuter J. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr 2012;61:208-215.
56. Wewers ME, Neidig JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. J Assoc Nurses AIDS Care 2000;11:37-44.
57. Zwiebel MA, Hughes V. Smoking cessation efforts in one New York City HIV clinic. J Assoc Nurses AIDS Care 2010;21:11-15.
58. Gelman M, King MA, Neal DE, Pacht ER, Clanton TL, Diaz PT. Focal air trapping in patients with HIV infection: CT evaluation and correlation with pulmonary function test results. Am J Roentgenol 1999;172:1033-1038.